• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Bind Biosciences

edit

BIND Biosciences, Inc. operates as a biopharmaceutical company and develops and commercializes therapeutic targeted nanoparticles for the treatment of cancer, inflammatory, infectious, and cardiovascular diseases. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.

Milestones

edit

• 
  Bind Biosciences added Andrea Franz as CFO.
  Posted 1/12/10 at 5:53am
• 
  Bind Biosciences added Jim Wright as Chief Scientific Officer.
  Posted 1/12/10 at 5:53am
• 
  Bind Biosciences added Scott Minick as President & CEO.
  Posted 1/12/10 at 5:53am
• 
  Bind Biosciences received $25.5M in Series D funding. (2/13/12)
  Posted 2/13/12 at 3:12am via onbiovc.com
• 
  Bind Biosciences received $47.3M in Venture Round funding. (10/27/11)
  Posted 10/27/11 at 7:32pm via fiercebiotech.com
• 
  Bind Biosciences received $4.75M in Debt funding. (10/13/11)
  Posted 10/13/11 at 8:35pm via masshightech.com
• 
  Bind Biosciences received $12.4M in Series C funding. (6/29/10)
  Posted 6/29/10 at 5:09pm via fiercebiotech.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/12/10

Sources

1. Bind banks $12.4M round as lead program heads into PhI Read more: Bind banks $12.4M round as lead program heads into PhI - FierceBiotech http://www.fiercebiotech.com/story/bind-banks-12-4m-round-lead-program-heads-phi/2010-06-29?utm_medium=rss&utm_source (fiercebiotech.com) [edit]
2. Bind Biosciences brings in $4.75M in debt funding (masshightech.com) [edit]
3. Russian fund leads $94.5M investment in two Langer biotechs (fiercebiotech.com) [edit]
4. Bind Biosciences, Inc.: Series D $25.5M (onbiovc.com) [edit]